Literature DB >> 19214139

From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics.

Larry F Chu1, De-Yong Liang, Xiangqi Li, Peyman Sahbaie, Nicole D'arcy, Guochun Liao, Gary Peltz, J David Clark.   

Abstract

OBJECTIVES: Addiction to opioid narcotics represents a major public health challenge. Animal models of one component of addiction, physical dependence, show this trait to be highly heritable. The analysis of opioid dependence using contemporary in-silico techniques offers an approach to discover novel treatments for dependence and addiction.
METHODS: In these experiments, opioid withdrawal behavior in 18 inbred strains of mice was assessed. Mice were treated for 4 days with escalating doses of morphine before the administration of naloxone allowing the quantification of opioid dependence. After haplotypic analysis, experiments were designed to evaluate the top gene candidate as a modulator of physical dependence. Behavioral studies as well as measurements of gene expression on the mRNA and protein levels were completed. Finally, a human model of opioid dependence was used to quantify the effects of the 5-HT3 antagonist ondansetron on signs and symptoms of withdrawal.
RESULTS: The Htr3a gene corresponding to the 5-HT3 receptor emerged as the leading candidate. Pharmacological studies using the selective 5-HT3 antagonist ondansetron supported the link in mice. Morphine strongly regulated the expression of the Htr3a gene in various central nervous system regions including the amygdala, dorsal raphe, and periaqueductal gray nuclei, which have been linked to opioid dependence in previous studies. Using an acute morphine administration model, the role of 5-HT3 in controlling the objective signs of withdrawal in humans was confirmed.
CONCLUSION: These studies show the power of in-silico genetic mapping, and reveal a novel target for treating an important component of opioid addiction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19214139      PMCID: PMC2730361          DOI: 10.1097/FPC.0b013e328322e73d

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  67 in total

1.  Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors.

Authors:  C A Brady; I M Stanford; I Ali; L Lin; J M Williams; A E Dubin; A G Hope; N M Barnes
Journal:  Neuropharmacology       Date:  2001-08       Impact factor: 5.250

Review 2.  Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy.

Authors:  Jianren Mao
Journal:  Pain       Date:  2002-12       Impact factor: 6.961

3.  Advantages of mRNA amplification for microarray analysis.

Authors:  A L Feldman; N G Costouros; E Wang; M Qian; F M Marincola; H R Alexander; S K Libutti
Journal:  Biotechniques       Date:  2002-10       Impact factor: 1.993

4.  Genetic variation in morphine analgesic tolerance: a survey of 11 inbred mouse strains.

Authors:  Benjamin Kest; Eileen Hopkins; Christina A Palmese; Michael Adler; Jeffrey S Mogil
Journal:  Pharmacol Biochem Behav       Date:  2002-11       Impact factor: 3.533

5.  Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence.

Authors:  B Kest; C A Palmese; E Hopkins; M Adler; A Juni; J S Mogil
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

6.  Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine.

Authors:  M Doverty; A A Somogyi; J M White; F Bochner; C H Beare; A Menelaou; W Ling
Journal:  Pain       Date:  2001-08       Impact factor: 6.961

Review 7.  Transcriptional regulation in acute promyelocytic leukemia.

Authors:  R J Lin; T Sternsdorf; M Tini; R M Evans
Journal:  Oncogene       Date:  2001-10-29       Impact factor: 9.867

8.  Voluntary oral morphine self-administration in rats: effect of haloperidol or ondansetron.

Authors:  P J Borg; D A Taylor
Journal:  Pharmacol Biochem Behav       Date:  1994-03       Impact factor: 3.533

9.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

10.  Influence of 5-HT3 receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats.

Authors:  G A Higgins; Y Wang; W A Corrigall; E M Sellers
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

View more
  28 in total

1.  A Flawed Design Produces Flawed Results.

Authors:  Gary Peltz
Journal:  J Addict Med       Date:  2018 May/Jun       Impact factor: 3.702

2.  Availability of dopamine and serotonin transporters in opioid-dependent users--a two-isotope SPECT study.

Authors:  Tzung Lieh Yeh; Kao Chin Chen; Shih-Hsien Lin; I Hui Lee; Po See Chen; Wei Jen Yao; Sheng-Yu Lee; Yen Kuang Yang; Ru-Band Lu; Mei-Hsiu Liao; Nan-Tsing Chiu
Journal:  Psychopharmacology (Berl)       Date:  2011-09-01       Impact factor: 4.530

3.  Agonist- and antagonist-induced up-regulation of surface 5-HT3 A receptors.

Authors:  Russell A Morton; Daniel T Baptista-Hon; Tim G Hales; David M Lovinger
Journal:  Br J Pharmacol       Date:  2015-07-06       Impact factor: 8.739

4.  The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery.

Authors:  Kevin C Greer; Abdullah S Terkawi; Siny Tsang; Priyanka Singla; Marcel E Durieux; Mohamed Tiouririne
Journal:  Reg Anesth Pain Med       Date:  2017 Sep/Oct       Impact factor: 6.288

5.  Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control.

Authors:  Larry F Chu; Tom Rico; Erika Cornell; Hannah Obasi; Ellen M Encisco; Haley Vertelney; Jamison G Gamble; Clayton W Crawford; John Sun; Anna Clemenson; Matthew J Erlendson; Robin Okada; Ian Carroll; J David Clark
Journal:  Drug Alcohol Depend       Date:  2017-08-14       Impact factor: 4.492

6.  α7 Nicotinic acetylcholine receptors in the central amygdaloid nucleus alter naloxone-induced withdrawal following a single exposure to morphine.

Authors:  Shigeru Ishida; Yoichi Kawasaki; Hiroaki Araki; Masato Asanuma; Hisashi Matsunaga; Toshiaki Sendo; Hiromu Kawasaki; Yutaka Gomita; Yoshihisa Kitamura
Journal:  Psychopharmacology (Berl)       Date:  2010-12-02       Impact factor: 4.530

7.  Ondansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy.

Authors:  Larry F Chu; John Sun; Anna Clemenson; Matthew J Erlendson; Tom Rico; Erika Cornell; Hannah Obasi; Zahra N Sayyid; Ellen M Encisco; Jeff Yu; Jamison G Gamble; Ian Carroll; J David Clark
Journal:  J Addict Med       Date:  2017 Sep/Oct       Impact factor: 3.702

8.  Preprotachykinin-A gene disruption attenuates nociceptive sensitivity after opioid administration and incision by peripheral and spinal mechanisms in mice.

Authors:  Peyman Sahbaie; Xiaoyou Shi; Xiangqi Li; Deyong Liang; Tian-Zhi Guo; Yanli Qiao; David C Yeomans; Wade S Kingery; J David Clark
Journal:  J Pain       Date:  2012-10       Impact factor: 5.820

9.  Repeated Forced Swim Exacerbates Methamphetamine-Induced Neurotoxicity: Neuroprotective Effects of Nanowired Delivery of 5-HT3-Receptor Antagonist Ondansetron.

Authors:  José Vicente Lafuente; Aruna Sharma; Dafin F Muresanu; Asya Ozkizilcik; Z Ryan Tian; Ranjana Patnaik; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

10.  Opiate-induced changes in brain adenosine levels and narcotic drug responses.

Authors:  M Wu; P Sahbaie; M Zheng; R Lobato; D Boison; J D Clark; G Peltz
Journal:  Neuroscience       Date:  2012-10-22       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.